The present invention relates to the treatment of cancers, such as a prostate cancer (e.g., castration-resistant prostate cancer (CRPC)). More specifically, the invention concerns the treatment of human patients having a prostate cancer (e.g., CRPC, e.g., metastatic CRPC) with a combination therapy including an PD-1 axis binding antagonist and an antiandrogen.